Looking at four building blocks of success, Wolfram Lux and Simone Seiter investigate what it takes to win and be successful when commercializing an orphan drug
Wolfram Lux and Simone Seiter
Advertisement
Dr. Wolfram Lux is a Senior Director and Dr. Simone Seiter is a Partner in the global Pharma & Biotech practice within Simon-Kucher & Partners Life Sciences Division (Frankfurt, Germany).
Articles by Wolfram Lux and Simone Seiter
Advertisement
Latest Updated Articles
- Commercializing an Orphan Drug: Why “Just” Serving a High Unmet Medical Need Won’t Do the Job
Published: September 8th 2020 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Bristol Myers Squibb Enters $1.5 Billion Definitive Agreement Acquiring Orbital Therapeutics
2
Most Favored Nation Order: Legal Battles, Market Shifts, and the Future of Drug Pricing Reform
3
FDA Approves Libtayo for Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma
4
Novo Nordisk Enters $4.7 Billion Definitive Agreement with Akero Therapeutics
5
